The Life Science Feed
Podcast
Deep dives with clinicians, researchers, and industry leaders.
All episodes
EULAR 2026: Key Rheumatology Trials to Watch
Anticipated trials at EULAR 2026 will address unmet needs in psoriatic arthritis and systemic lupus erythematosus, focusing on novel therapeutic targets.

Cataract Surgery: 4 Underappreciated Clinical Considerations
Cataract surgery, while common, presents nuances often overlooked in routine practice. This article details four less-known aspects.

Biologics Offer Targeted Efficacy in Psoriasis Management
Biologic therapies have significantly advanced psoriasis treatment by targeting specific immune pathways, offering improved outcomes for patients.

Myasthenia Gravis in Pregnancy: Exacerbations Common in Peripartum
Myasthenia gravis (MG) in pregnancy presents diagnostic and management challenges, with exacerbations common in the first trimester and postpartum period.

Amyloid Therapies Show Limited Cognitive Benefit in Alzheimer's
Amyloid-beta targeting therapies for Alzheimer's disease demonstrate modest effects on cognitive decline, with clinical significance remaining uncertain.

CAR T-Cell Therapy Shows Efficacy in Refractory Autoimmune Disease
CAR T-cell therapy, traditionally for cancer, demonstrates potential in severe autoimmune conditions, offering a new therapeutic avenue.

Yoga Reduces Insomnia, Fatigue, Anxiety in Cancer Survivors
A new study presented at ASCO 2026 demonstrates yoga significantly improves insomnia, fatigue, and anxiety in cancer survivors.

COVID Not Primary Driver of Pediatric Type 1 Diabetes Rise
Evidence suggests the observed increase in pediatric type 1 diabetes predates the COVID-19 pandemic, indicating other factors are at play.
Stay ahead in
Life Science.

Doctor-Patient Communication Improves Treatment Acceptance in Cancer
Effective doctor-patient communication, focusing on patient self-blame, significantly increases treatment acceptance rates in cancer patients.

Tile Radiation for Large Brain Mets: A New Approach at ASCO 2026
Tile-based radiation therapy for large brain metastases was presented at ASCO 2026, offering a novel strategy for dose escalation.

More Breast Cancer Patients Can Skip Axillary Dissection
New data presented at ASCO 2026 indicates an expanded cohort of breast cancer patients can safely omit axillary lymph node dissection.
HYRNUO® (Sevabertinib) Shows Efficacy in Advanced Solid Tumours
6 min readOncodetect® MRD Test Shows Analytical Validity, Clinical Utility at ASCO
6 min readTACE + Camrelizumab/Rivoceranib Improves OS in Unresectable HCC
5 min readSubcutaneous Immunotherapy Offers Alternative Administration at ASCO 2026
6 min readMCED Tests Show Promise for Earlier Cancer Detection at ASCO 2026
6 min readMLVs: Dual Role in Brain Metastases Offers Therapeutic Targets
5 min read
Alcohol and Sugar: A Dual Metabolic Challenge for Patients
Patients consuming alcohol and high-sugar diets face a compounded metabolic risk, impacting liver function and glucose regulation. Clinicians must address both factors.

EASL Congress 2026: Key Trials to Watch in Liver Disease Management
EASL Congress 2026 will feature pivotal trials in NAFLD/NASH, HBV, and HCC, potentially reshaping current treatment paradigms.

Variceal Bleeding Management: EASL 2026 Skills Centre Focuses on Endoscopic and Pharmacological Strategies
EASL 2026 Skills Learning Centre will address variceal bleeding, highlighting current evidence for endoscopic and pharmacological interventions.
EASL 2026: Liver and Spleen Elastography for Fibrosis Assessment
6 min readEASL 2026 Forum: Enhancing Patient-Clinician Communication
6 min readEASL 2026: Alcohol Policy Action Needed for Liver Disease
6 min readA-TANGO Score Refines ACLF Diagnosis, Prognosis in Cirrhosis
6 min readMASLD Diagnosis Faces Barriers Despite 2024 EASL Guidelines
5 min readEASL 2026: Non-invasive Diagnostics Advance Liver Disease Staging
7 min read
Managing Acute Heart Failure And Cardiogenic Shock
Acute decompensated heart failure drives over one million hospital admissions annually. 30-day readmission rates are 25%. When the heart cannot compensate, the tools change entirely - IV diuretics, inotropes, mechanical circulatory support. Sarah Mitchell and James Carter cover ADHF management, cardiogenic shock, and how to prevent the revolving door.

Semaglutide For Obese Heart Failure Patients
More than 80% of HFpEF patients are overweight or obese. STEP-HFpEF showed semaglutide 2.4mg improved symptoms by 16 points on the KCCQ and reduced weight by 13.3% - now a Class IIa ESC recommendation. Sarah Mitchell and James Carter explore why treating the metabolic environment is the new paradigm for HFpEF.

Diabetes Drugs For Stiff Heart Failure
Heart failure with preserved ejection fraction accounts for more than half of all HF diagnoses. For two decades every major drug trial failed. Then SGLT2 inhibitors changed everything - twice. Sarah Mitchell and James Carter explain why HFpEF was so hard, and what finally worked.
How Four Drugs Beat Heart Failure
1 min readTricuspid Valve Surgery Benefits Adults with Systemic Right Ventricle
6 min readDual Plane Block May Cut Opioid Use After Bypass Surgery
6 min readPAHO's HEARTS 2.0 Outlines 38-Step Pathway for Cardio-Renal Care
6 min readRight Heart Catheterization: ATS 2026 Clarifies Waveform Interpretation
7 min readPrimary LV Unloading in Anterior STEMI Shows No Benefit in STEMI-Door to Unload Trial
6 min read
2026 Dyslipidemia Guideline: Utility in Family Medicine Assessed
A new assessment tool, G-TRUST, evaluates the relevance and trustworthiness of cardiovascular risk guidelines, including statin recommendations.

The GLP-1 Muscle Loss Dilemma

The Velvet Rope Of Weight Loss Drugs
GLP-1 Drugs Protect Hearts And Kidneys
1 min readRewiring The Brain To Silence Food Noise
1 min readCOVID Not Primary Driver of Pediatric Type 1 Diabetes Rise
6 min readTirzepatide: Efficacy in Weight Management Explored at ATS 2026
6 min readLower-Dose Tirzepatide: Can It Sustain Weight Loss Long-Term?
7 min readOral Orforglipron Sustains Weight Loss After Injectable GLP-1 Therapy
6 min read
Reassuring Data for High-Efficacy MS Meds in Pregnancy
New data provide reassurance regarding the use of high-efficacy multiple sclerosis therapies during pregnancy, addressing a significant clinical dilemma.

Amyloid Therapies Show Limited Cognitive Benefit in Alzheimer's
Amyloid-beta targeting therapies for Alzheimer's disease demonstrate modest effects on cognitive decline, with clinical significance remaining uncertain.

CGRP Inhibitors for Migraine: CV Safety Data Limited in High-Risk Patients
CGRP-targeted therapies are effective for migraine prevention, but cardiovascular safety data is limited in patients with established vascular disease.
Amyloid Therapies Show Limited Cognitive Benefit in AD
4 min readPARP1 Deficiency Reduces Amyloid Pathology in Familial AD Model
6 min readBrain Cooling After Thrombectomy: Does Hypothermia Aid LVO Recovery?
6 min readGut Microbiota Signal the Brain via the Vagus Nerve: What GPs Should Know
7 min readLow-Dose Lithium for Cognitive Decline: What the Evidence Actually Shows
7 min readParkinson's Neuroprotection 2025: Three Strategies Under Review
5 min read






































